← Browse by Condition
Medical Condition
locally advanced esophageal squamous cell carcinoma
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2
ClinicalMetric tracks all active clinical trials for locally advanced esophageal squamous cell carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 2 2
Top Sponsors
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06187597 Phase 2
Recruiting
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
Enrollment
140 pts
Location
China
Sponsor
Sun Yat-sen University
NCT07549100
Recruiting
Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
Enrollment
30 pts
Location
China
Sponsor
Shandong Provincial Hospital
NCT06843889 Phase 2
Recruiting
A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
Enrollment
34 pts
Location
China
Sponsor
Nanfang Hospital, Southern Med...
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology